secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK:        0000882796
Form:       8-K
Filed at:   2023-08-03T23:59:59+00:00
Accession:  0001171843-23-004942
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioCryst Q2 ORLADEYO rev $81M (+24% YoY); on track for FY $320M; GAAP EPS ($0.40)
--------------------------------------------------------------------------------

- ORLADEYO net revenue $81.0M in Q2 2023, up 24.2% YoY from $65.2M; total revenues $82.5M (+25.9% YoY).
- GAAP net loss $75.3M ($0.40/share) vs $58.9M ($0.32/share) in Q2 2022; includes $29M one-time debt extinguishment fee.
- Non-GAAP EPS ($0.24) after excluding the one-time fee; operating cash use $13.5M in Q2.
- Reaffirmed FY 2023 ORLADEYO revenue guidance of >=$320M; peak revenue target $1B.
- R&D day set for Nov 3, 2023 to introduce pipeline assets; BCX10013 trial enrollment in PNH expected by year-end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882796/000117184323004942/0001171843-23-004942-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882796/000117184323004942/f8k_080323.htm
  HTML page:      https://secwatch.observer/filing/0001171843-23-004942

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer